Physician profile
Jerald Insel
NPI 1871561043
$29,243.96
in general payments reported to CMS, 2019-2025
37 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $397 · 2021: $962 · 2022: $5,374 · 2023: $5,747 · 2024: $566 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $1,967 · Travel and Lodging: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $1,967.26 |
| Travel and Lodging | $602.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14,883.92 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $7,921.46 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,290.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $910.12 | 2019-2025 | |
| Abiomed | $734.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.35 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $487.33 | 2019-2022 | |
| Amgen INC. | $328.81 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $268.07 | 2019-2025 | Farxiga, Lokelma |
| Scpharmaceuticals INC. | $241.64 | 2023-2025 | |
| Pfizer INC. | $233.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $198.30 | 2021-2024 | Verquvo |
| Medtronic Vascular, INC. | $175.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $154.59 | 2020-2021 | |
| Atricure, INC. | $111.60 | 2025 | Atriclip Laa Exclusion System |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Insel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.